Annovis Bio Inc. announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap.
This newly issued patent is based on buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With this latest approval in the U.S., the company now holds global protection for the use of buntanetap in treating acute neurodegenerative disorders.
“Nerve cells are inherently delicate and susceptible to structural damage upon physical impact. Buntanetap works by targeting the neurotoxic pathways that contribute to this damage, providing a potential path to protect and restore neuronal health,” commented Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “We are proud to add this patent to our growing intellectual property portfolio, further expanding the possible applications of buntanetap beyond its primary indications such as Alzheimer’s and Parkinson’s diseases.”
The U.S. Patent and Trademark Office (USPTO) issued the patent on January 2, 2025, under the publication number US-2025-0000846-A1.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!